Sequential pharmacological therapies in the management of macular oedema secondary to retinal vein occlusion
|
|
- Alvin Williams
- 6 years ago
- Views:
Transcription
1 Northern (NHS) Treatment Advisory Group Sequential pharmacological therapies in the management of macular oedema secondary to retinal vein occlusion Author: Paul Madill Specialty Registrar in Public Health February 2014 N-TAG 2014
2 Introduction Retinal vein occlusion is a common vascular abnormality associated with conditions such as hypertension, diabetes, glaucoma and other vascular and haematological disorders. One of the consequences of occluded veins in the retina is impaired haemostatic clearance leading to increased pressure in the retinal vasculature. This is turn can damage the retinal microvasculature causing the vessels to leak or haemorrhage. The leakage will affect the macular and lead to macular oedema, a common cause of loss of visual acuity and blindness in patients with retinal vein occlusions. The macula is the central part of the retina responsible for colour vision and perception of fine detail (i.e. visual acuity). Other complications of retinal vein occlusion include vitreous haemorrhage, ischaemia and neovascularisation, all of which can cause or compound loss of vision. [1-3] The condition is sub-divided into two main classifications; either central (CRVO) or branch retinal vein occlusion (BRVO) depending on the site of vascular occlusion. This distinction is important with respect to the prognosis and treatment parameters. Generally, CRVO will result in greater visual impairment than BRVO and is more difficult to treat. More than one BRVO may exist, and BRVO may also exist in conjunction with CRVO. Usually only one eye is symptomatic although bilateral retinal vein occlusions are relatively common. Symptomatic BRVO is about twice as common as CRVO. [1-3] The annual incidence of RVO has been estimated based on a 15-year study which reported 500 new cases of CRVO and 1,800 cases of BRVO per 100,000 people aged 43 to 84 years. [4,5] The National Institute for Health & Care Excellence (NICE) has estimated that 22 patients per 100,000 of the population would require pharmacological treatment for RVO. [6] It is not known what proportion of these patients may require sequential pharmacological treatment. In BRVO laser therapy is used to restore visual acuity where visual loss is not severe. Restoring visual acuity in patients with macular oedema secondary to CRVO is more difficult and laser therapy is not used as studies have demonstrated no improvement [1,7] NICE has recommended two pharmacological treatments for macular oedema secondary to RVO (box 1), differentiated according to whether the occlusion is central or branch. [1,6] Northern (NHS) Treatment Advisory Group 1
3 Box 1. NICE recommendations for pharmacological treatment of RVO Dexamethasone intravitreal implant (Ozurdex ) Dexamethasone intravitreal implant is recommended as an option for the treatment of macular oedema following BRVO when treatment with laser photocoagulation has not been beneficial or is not considered suitable because of the extent of macular haemorrhage. [1] Dexamethasone intravitreal implant is recommended as an option for the treatment of macular oedema following CRVO. [1] Ranibizumab (Lucentis ) Ranibizumab is recommended as an option for treating visual impairment caused by macular oedema following BRVO when treatment with laser photocoagulation has not been beneficial or is not considered suitable because of the extent of macular haemorrhage. [6] Ranibizumab is recommended as an option for treating visual impairment caused by macular oedema following CRVO. [6] Ozurdex (Allergan Pharmaceuticals) is a biodegradable ocular implant that contains dexamethasone and is licensed for the treatment of macular oedema secondary to branch or central retinal vein occlusion. It is available in a complete drug delivery system for intraviteal injection directly through the white (sclera) of the eye. The implant contains 700 micrograms of dexamethasone which is slowly and inconsistently released over a period of six months. Its principal mode of action in macular oedema is believed to be via inhibition of vascular endothelial growth factor (VEGF), thus inhibiting the growth of new blood vessels which are often leaky and which can themselves obscure vision. [8-11] The target frequency for administration of Ozurdex, based on experience in clinical studies, is six-monthly and it is not recommended that two eyes are treated concurrently. [8,12-14] Northern (NHS) Treatment Advisory Group 2
4 Ranibizumab (Lucentis, Novartis) belongs to a class of drugs that specifically block the action of VEGF. In RVO vision is reduced as a result of retinal vascular disease. Thromboses in the retinal veins can increase retinal capillary pressure, resulting in increased capillary permeability and the discharge of blood and plasma into the retina. This leads to macular oedema and varying levels of ischaemia through reduced perfusion of capillaries. These changes trigger an increase in VEGF, which increases vascular permeability and new vessel proliferation. [6] By inhibiting the action of VEGF ranibizumab can reduce oedema and limit visual loss or improve vision. Hence the basis for inhibiting VEGF in RVO. [6] Bevacizumab (Avastin, Roche) is a distinctly different molecule to ranibizumab although its pharmacological activity is identical. Despite not being licensed for ophthalmic use it is used in various ophthalmic indications including RVO outside of its product license.[15] Ranibizumab and bevacizumab are typically administered via intravitreal injection at monthly intervals initially and then as required depending on response. [15] The Northern (NHS) Treatment Advisory Group (N-TAG) has been requested to conduct an appraisal of, and issue a subsequent recommendation in relation to, the sequential pharmacological treatment of macular oedema secondary to retinal vein occlusion with Ozurdex after ranibizumab or bevacizumab, or with ranibizumab or bevacizumab after Ozurdex. The scope of this appraisal will relate principally to pharmacological treatments for RVO which have been recommended by NICE. [1,6] In addition, due to the biological commonalities between ranibizumab and bevacizumab, the latter drug, although not licensed for RVO, will also be considered within the scope of this appraisal. Northern (NHS) Treatment Advisory Group 3
5 Clinical evidence Only one directly relevant source of evidence for the sequential use of treatments within the scope of this appraisal was identified. [16] This involved the use of Ozurdex after a lack of response with bevacizumab. This small retrospective review of records (n = 18) found modest but clinically significant benefits from a switch in therapy to Ozurdex. [16] Other useful evidence of less relevance includes a non-comparative prospective study of dual therapy with bevacizumab and Ozurdex. [17] Patients (n eyes = 34) received intravitreal bevacizumab followed two weeks later with an Ozurdex implant. Overall results in terms of visual acuity and macular thickness were positive, and the authors reported a lower than expected re-treatment rate after six months. [17] In a similar study patients were treated with three monthly loading doses of bevacizumab followed by an Ozurdex implant (n eyes = 26) compared with Ozurdex alone (n eyes = 38). Results at six months did not support the use of combination therapy compared with Ozurdex monotherapy. [18] The key studies which supported the license for ranibizumab in RVO (CRUISE and BRAVO) specifically excluded patients with recent prior treatment of any nature. [19,20] The key study of Ozurdex in RVO (GENEVA) was conducted before ranibizumab was commercially available for RVO and is unlikely to have been a common prior treatment. [21] Northern (NHS) Treatment Advisory Group 4
6 Safety In the limited evidence relating to sequential treatment safety outcomes were poorly reported. No new or unexpected adverse effects or other safety sequalae were reported. [16] Both Ozurdex and ranibizumab have been in use for a number of years for various indications and have established an acceptable risk:benefit ratio. There are differences in the treatments which could lead to theoretical differences in safety profiles. For example, Ozurdex is administered less frequently with one implant per eye once every four to six months, [12] whereas ranibizumab and bevacizumab may be administered as frequently as monthly, with regular monthly check-ups in the interim. [15] The Ozurdex needle is slightly larger than those usually used for intravitreal injections. [12] No direct comparative evidence was identified to show that needle size or injection frequency affect adverse effect rates. Both treatment modalities are associated with raised intra-ocular pressure (IOP). Although not in direct comparison, Ozurdex does appear to be associated with a greater frequency and severity of raised IOP than intravitreal bevacizumab or ranibizumab. In the pivotal GENEVA study [21] and evidence from practice [22], about 1 in 4 or 1 in 5 Ozurdex patients experience raised IOP which required at least one medication to control the IOP. Medication used to manage IOP is usually in the form of a topical eye drop. However, raised IOP associated with ranibizumab is usually transient persisting for less than one day, and is believed to be related to an intraocular volume increase. Northern (NHS) Treatment Advisory Group 5
7 Cost analysis Costs include VAT at 20% unless otherwise indicated. Separately, both ranibizumab and Ozurdex have been determined as cost effective for the NHS, [1,6] with a substantial mandatory discount conditional on the use of ranibizumab. [6] However no evidence was identified concerning the cost-effectiveness of a treatment switch from one treatment strategy to another. Bevacizumab is substantially less costly than ranibizumab [15] but is not widely used in RVO due to a lack of robust evidence and product license. The NICE costing template which accompanied the ranibizumab for RVO technology appraisal estimated a mature RVO treatment cohort of about 2,000 patients per annum for the North East & Cumbria of whom only about 625 would require pharmacological treatment. [6] An unknown, but likely to be minority, proportion of these patients may be considered suitable for or otherwise require a switch in treatment strategy. The NICE cost template for ranibizumab (Lucentis ) in RVO does not model prior or subsequent treatment with Ozurdex. [6] Each Ozurdex implant costs 1,044 each. [23] Ranibizumab (Lucentis ) is available at a substantial discount to the NHS and costs 534 per dose. [24] Bevacizumab intravitreal syringes can be purchased from licensed compounding facilities typically at less than 100 per dose. [15] Administration costs will be the same per episode at about 400 regardless of treatment modality. However bevacizumab and ranibizumab will require more frequent administration (estimated 7 to 9 injections in the first year) and patients will require monthly monitoring. [6,15] Northern (NHS) Treatment Advisory Group 6
8 Points to consider Given the absence of good quality clinical evidence to support any switching or sequential pharmacological RVO treatment strategy, any decision to change between one therapeutic modality to another should be based upon non-clinical or safety factors. A draft treatment protocol from the North East Retinal Group has indicated the following points for switching therapy: Nil, or diminished, or suboptimal clinical response Raised and uncontrolled IOP with Ozurdex Allergy, hypersensitivity, anaphylaxis or other toxic response or other disabling side effects to first therapy None of these points is specifically supported by any direct clinical evidence. Some of points, whilst appearing to be rationale, are not further qualified with specific criteria. For example no threshold for IOP has been specified and neither has uncontrolled been defined. With respect to other adverse effects, clarification has not been provided concerning other disabling side effects or other toxic response. It is not clear to what extent patient choice can or should be accommodated should a patient, for any reason, wish to change their treatment modality at any point in the course of their condition. The second point relating to intra-ocular pressure may be a rational option given that the incidence of raised IOP is recognised as being a significant adverse effect associated with Ozurdex in particular, although it does occur with ranibizumab too. In the GENEVA study 24% of patients required medication to help manage IOP. An unknown proportion of these may experience uncontrolled raised IOP even with the use of medications. Raised IOP is listed as a very common (i.e. incidence > 10%) adverse effect associated with ranibizumab. It is not known whether the incidence of raised IOP with one treatment would be independent of the risk with the other treatment. The treatments are by no means similar in their administration and dosing. For example Ozurdex is only indicated once every six months at the most frequent, whereas ranibizumab is licensed for monthly administration initially. Ozurdex requires injection with a larger bore needle at an oblique angle into the sclera (white) of the eye whereas intravitreal injections of ranibizumab are administered using a finer needle through a more direct path. Northern (NHS) Treatment Advisory Group 7
9 Although not specifically precluded by NICE guidance, a switch from one treatment strategy to another would not have been considered by NICE as this was not a feature of the supporting evidence. Whether a treatment decision can be taken in isolation of prior RVO treatment modalities for the same indication is not entirely clear from current NICE recommendations. NICE guidance does refer to prior use of laser photocoagulation in the treatment of BRVO for both treatments but only as a pre-condition or consideration before using either ranibizumab or Ozurdex. The commissioning liabilities for managing access based on prior RVO treatments therefore remains untested. It may be desirable or preferable to allow any adverse sequalae leading to a therapeutic switch to completely resolve before a new treatment strategy is initiated. References 1. NICE. TA 229: Dexamethasone intravitreal implant for the treatment of macular oedema secondary to retinal vein occlusion RCO. Retinal Vein Occlusion (RVO) Interim guidelines. Royal College of Opthalmologists, Yau JWY, Lee P, Wong TY, Best J, Jenkins A. Retinal vein occlusion: an approach to diagnosis, systemic risk factors and management. Internal medicine journal. 2008;38(12): Horsley W. Intravitreal dexamethasone implant (Ozurdex ) for macular oedema associated with retinal vein occlusion. NETAG, Klein R, Moss SE, Meuer SM, Klein BEK. The 15-year cumulative incidence of retinal vein occlusion: the Beaver Dam Eye Study. Archives of ophthalmology. 2008;126(4): NICE. TA 283 Ranibizumab for treating visual impairment caused by macular oedema secondary to retinal vein occlusion National Institute for Health and Care Excellence (NICE), McIntosh RL, Rogers SL, Lim L, Cheung N, Wang JJ, Mitchell P, et al. Natural history of central retinal vein occlusion: an evidence-based systematic review. Ophthalmology. 2010;117(6): e National Institute for Health and Clinical Excellence. Draft scope (pre-referral) for dexamethasone intravitreal implant for the treatment of macular oedema caused by retinal vein occlusion. January Summary of product characteristics. Ozurdex (Allergan ltd). Accessed September Commercial information available online via Accessed September 2010 Northern (NHS) Treatment Advisory Group 8
10 11. Anon. Advance notification document: Dexamethasone 700 µg intravitreal implant in applicator (OZURDEX ) for retinal vein occlusion. Allergan, October Summary of product characteristics. Ozurdex (Allergan ltd). Accessed September Commercial information available online via Accessed September Anon. Advance notification document: Dexamethasone 700 µg intravitreal implant in applicator (OZURDEX ) for retinal vein occlusion. Allergan, October Horsley W. Anti-vascular endothelial growth factor therapies (bevacizumab and ranibizumab) in the management of macular oedema secondary to retinal vein occlusions. North East Treatment Advisory Group, Sharareh B, Gallemore R, Taban M et al. Recalcitrant macular edema after intravitreal bevacizumab is responsive to an intravitreal dexamethasone implant in retinal vein occlusion. Retina 2013;33(6): Singer MA, Bell DJ, Woods P et al. Effect of combination therapy with bevacizumab and dexamethasone intravitreal implant in patients with retinal vein occlusion. Retina 2012; 32(7): Mayer WJ, Remy M, Wolf A et al. Comparison of intravitreal bevacizumab upload followed by a dexamethasone implant versus dexamethasone implant monotherapy for retinal vein occlusion with macular edema. Ophthalmologica 2012;228(2): Brown DM, Campochiaro PA, Singh RP, Li Z, Gray S, Saroj N, et al. Ranibizumab for macular edema following central retinal vein occlusion: six-month primary end point results of a phase III study. Ophthalmology. 2010;117(6): e De Niro JE, Fu AD, Johnson RN, McDonald HR, Jumper JM, Cunningham E, et al. Intravitreous ranibizumab for persistent macular edema in retinal vein occlusion unresponsive to bevacizumab. Retinal Cases and Brief Reports. 2013;7(3): Haller JA, Bandello F, Belfort Jr R, Blumenkranz MS, Gillies M, Heier J, et al. Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion. Ophthalmology. 2010;117(6): e Papathomas T, Tsagkataki M, Kumar I, Kamal A. Safety and efficacy of dexamethasone intravitreal implant in macular oedema due to retinal vein occlusions 1 year follow up. Poster presentation, ARVO, Seattle, NHS dictionary of medicines and devices. February North East & Cumbria regional pharmacy procurement team Author s declaration: The author has no relevant interests to declare. The report editor has participated in non-promotional events, and advisory boards and similar, for both Allergan and Novartis. Northern (NHS) Treatment Advisory Group 9
Retinal Vein Occlusion (RVO) Treatment pathway- Northeast England. Retinal Vein Occlusion (RVO) with Macular oedema (MO)
Retinal Vein Occlusion (RVO) Treatment pathway- Northeast England (Royal Victoria Infirmary, Sunderland Eye Infirmary, James Cook University Hospital, Darlington Memorial Hospital, University Hospital
More informationMarie Tsaloumas Consultant Ophthalmic Surgeon Queen Elizabeth Hospital, Birmingham. bars 2014
Marie Tsaloumas Consultant Ophthalmic Surgeon Queen Elizabeth Hospital, Birmingham bars 2014 Declaration of interest I have sat on Advisory boards for Novartis and Bayer Involved in Novartis sponsored
More informationResearch Article http://www.alliedacademies.org/clinical-ophthalmology-and-vision-science/ A 2-year retrospective study of the treatment of retinal vein occlusion with dexamethasone 0.7 mg intravitreal
More informationEU Regulatory workshop Ophthalmology clinical development and scientific advice. Industry view on DME and macular edema secondary to RVO
EU Regulatory workshop Ophthalmology clinical development and scientific advice. Industry view on DME and macular edema secondary to RVO Yehia Hashad, M.D. Vice President and Global Therapeutic Area Head
More informationWhat you can expect with OZURDEX
Important Information About Macular Edema Following Branch or Central Retinal Vein Occlusion (RVO) and Treatment For patients with RVO What you can expect with OZURDEX Approved Use OZURDEX (dexamethasone
More informationMacular edema (ME) is the most common
MANAGEMENT OF RETINAL VEIN OCCLUSIONS * Peter A. Campochiaro, MD ABSTRACT Macular edema (ME) is the most common cause of reduced vision in patients with retinal vein occlusions (RVOs). The primary cause
More informationNATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE. Health Technology Appraisal. Aflibercept for treating diabetic macular oedema.
NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE Health Technology Appraisal Aflibercept for treating diabetic macular oedema Final scope Final remit/appraisal objective To appraise the clinical and cost
More informationTechnology appraisal guidance Published: 22 May 2013 nice.org.uk/guidance/ta283
Ranibizumab for treating visual impairment caused by macular oedema secondary to retinal vein occlusion Technology appraisal guidance Published: 22 May 2013 nice.org.uk/guidance/ta283 NICE 2018. All rights
More informationTechnology appraisal guidance Published: 27 July 2011 nice.org.uk/guidance/ta229
Dexamethasone intravitreal implant for the treatment of macular oedema secondary to retinal vein occlusion Technology appraisal guidance Published: 27 July 2011 nice.org.uk/guidance/ta229 NICE 2018. All
More informationResearch Article Differentiation between Good and Low-Responders to Intravitreal Ranibizumab for Macular Edema Secondary to Retinal Vein Occlusion
Hindawi Publishing Corporation Journal of Ophthalmology Volume 2016, Article ID 9875741, 6 pages http://dx.doi.org/10.1155/2016/9875741 Research Article Differentiation between Good and Low-Responders
More informationILUVIEN IN DIABETIC MACULAR ODEMA
1 ILUVIEN IN DIABETIC MACULAR ODEMA Marie Tsaloumas Consultant Ophthalmic Surgeon Queen Elizabeth Hospital, Birmingham bars conference 2104 1 2 Declaration of interest I have sat on Advisory boards for
More informationApplying New Data to Improve the Standard of Care in Retinal Diseases Managing Macular Edema Associated With Retinal Venous Occlusions
Supplement to November/December 2013 CME Activity Applying New Data to Improve the Standard of Care in Retinal Diseases Managing Macular Edema Associated With Retinal Venous Occlusions By Michael Singer,
More informationBevacizumab (Avastin ) for neovascular glaucoma secondary to ischaemic central retinal vein occlusion
Bevacizumab (Avastin ) for neovascular glaucoma secondary to ischaemic central retinal vein occlusion Author: William Horsley Lead Pharmacist for April 2011 2011 Summary Neovascular glaucoma is an acutely
More informationaflibercept 40mg/mL solution for injection (Eylea ) SMC No. (1074/15) Bayer
aflibercept 40mg/mL solution for injection (Eylea ) SMC No. (1074/15) Bayer 07 August 2015 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards
More informationSupplement to March Ranibizumab: Expanding Horizons in Retinal Vein Occlusion Management. Sponsored by Novartis Pharma AG
Supplement to March 2015 Ranibizumab: Expanding Horizons in Retinal Vein Occlusion Management Sponsored by Novartis Pharma AG Ranibizumab: Expanding Horizons in Retinal Vein Occlusion Management This supplement
More informationInformation for Patients undergoing Intravitreal Triamcinolone Acetonide (Kenalog) Injection
Information for Patients undergoing Intravitreal Triamcinolone Acetonide (Kenalog) Injection Kenalog/SS/ST/04.2012/v1.1 review 05.2013 Page 1 Introduction Your doctor has found that you have leakage of
More informationOphthalmic VEGF Inhibitors. Eylea (aflibercept), Macugen (pegaptanib) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: Ophthalmic VEGF Inhibitors Page: 1 of 5 Last Review Date: September 20, 2018 Ophthalmic VEGF Inhibitors
More informationComparison of Ranibizumab and Bevacizumab for Macular Edema Associated with Branch Retinal Vein Occlusion
pissn: 1011-8942 eissn: 2092-9382 Korean J Ophthalmol 2017;31(3):209-216 https://doi.org/10.3341/kjo.2015.0158 Original Article Comparison of Ranibizumab and Bevacizumab for Macular Edema Associated with
More informationOCCLUSIVE VASCULAR DISORDERS OF THE RETINA
OCCLUSIVE VASCULAR DISORDERS OF THE RETINA Learning outcomes By the end of this lecture the students would be able to Classify occlusive vascular disorders (OVD) of the retina. Correlate the clinical features
More informationTreatment of Retinal Vein Occlusion (RVO)
Manchester Royal Eye Hospital Medical Retina Services Information for Patients Treatment of Retinal Vein Occlusion (RVO) What is a Retinal Vein Occlusion (RVO)? The retina is the light sensitive layer
More informationVascular Disease Ocular Manifestations of Systemic Hypertension
Vascular Disease Ocular Manifestations of Systemic Hypertension Maynard L. Pohl, OD, FAAO Pacific Cataract & Laser Institute 10500 NE 8 th Street, Suite 1650 Bellevue, WA 98004 USA 425-462-7664 Cerebrovascular
More informationOphthalmology Macular Pathways
Ophthalmology Macular Pathways Age related Macular Degeneration Diabetic Macular Oedema Macular Oedema secondary to Central Retinal Macular Oedema secondary to Branch Retinal CNV associated with pathological
More informationDiabetic maculopathy 11/ An update on. Miss Vasuki Sivagnanavel
Miss Vasuki Sivagnanavel Consultant Ophthalmologist An update on Diabetic maculopathy Despite advances in the management of diabetes, diabetic retinopathy is already the commonest cause of blindness among
More informationRVO RETINAL VEIN OCCLUSION
RVO RETINAL VEIN OCCLUSION A guide to understanding RVO Take some time to learn about RVO - it may help you hold on to your vision Retinal vein occlusion is a common disorder of the retina and a leading
More informationAnti VEGF Agents in Retinal Disorders Current Scenario
Retina Anti VEGF Agents in Retinal Disorders Current Scenario Charu Gupta MS Charu Gupta MS, Cyrus M. Shroff MD Shroff Eye Centre, New Delhi T is a group of proteins involved in the regulation of angiogenesis,
More informationBevacizumab (Avastin ) in the management of neovascular age-related macular degeneration: Updated Appraisal
Bevacizumab (Avastin ) in the management of neovascular age-related macular degeneration: Updated Appraisal Author: William Horsley Lead Pharmacist for July 2011 2011 Summary did not recommend bevacizumab
More informationComparison of BRVO and CRVO management
Comparison of BRVO and CRVO management Francesco Bandello, MD, FEBO Department of Ophthalmology University Vita-Salute Scientific Institute San Raffaele Milan, Italy 1 Financial Disclosure Advisory Board
More informationAbbreviated Drug Evaluation: Fluocinolone acetonide intravitreal implant (Retisert )
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35, Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationFrom Outdated to Updated: A Review of Important Clinical Trials in Ocular Disease from 2014
From Outdated to Updated: A Review of Important Clinical Trials in Ocular Disease from 2014 1. This course is designed to review the important ophthalmic literature that was released between October 2013
More informationPRECISION PROGRAM. Injection Technique Quick-Reference Guide. Companion booklet for the Video Guide to Injection Technique
Injection Technique Quick-Reference Guide PRECISION PROGRAM Companion booklet for the Video Guide to Injection Technique Available at www.ozurdexprecisionprogram.com Provides step-by-step directions with
More informationDexamethasone posterior segment drug delivery system (Ozurdex) for diabetic macular oedema
Dexamethasone posterior segment drug delivery system (Ozurdex) for diabetic macular oedema This technology summary is based on information available at the time of research and a limited literature search.
More informationAn Update on Branch Retinal Vein Occlusion Treatment Studies. Amiee Ho, O.D. Pacific University College of Optometry
An Update on Branch Retinal Vein Occlusion Treatment Studies Amiee Ho, O.D. Pacific University College of Optometry Course Description This course focuses on current treatment options available for macular
More informationABSTRACT INTRODUCTION
DOI 10.1007/s40123-017-0114-6 ORIGINAL RESEARCH Real-World Cost Savings Demonstrated by Switching Patients with Refractory Diabetic Macular Edema to Intravitreal Fluocinolone Acetonide (Iluvien): A Retrospective
More informationA RETROSPECTIVE OBSERVATIONAL STUDY OF INTRAVITREAL OZURDEX IMPLANT IN TREATING MACULAR PERSISTEN EDEMA
A RETROSPECTIVE OBSERVATIONAL STUDY OF INTRAVITREAL OZURDEX IMPLANT IN TREATING MACULAR PERSISTEN EDEMA CRISTIAN TURLEA 1,MAGDALENA TURLEA 1,ILEANA ZOLOG 4, PAVEL FARCAS 2, ANDREI BRANCO TOMESCU 3 1 Department
More informationClinical Case Presentation. Branch Retinal Vein Occlusion. Sarita M. Registered Nurse Whangarei Base Hospital
Clinical Case Presentation on Branch Retinal Vein Occlusion Sarita M. Registered Nurse Whangarei Base Hospital Introduction Case Study Pathogenesis Clinical Features Investigations Treatment Follow-up
More informationThe Common Clinical Competency Framework for Non-medical Ophthalmic Healthcare Professionals in Secondary Care
The Common Clinical Competency Framework for Non-medical Ophthalmic Healthcare Professionals in Secondary Care Medical Retina November 2016 Association of Health Professions in Ophthalmology General basic
More informationYoshiro Minami 1*, Taiji Nagaoka 2, Akihiro Ishibazawa 1,2 and Akitoshi Yoshida 2
Minami et al. BMC Ophthalmology (2017) 17:90 DOI 10.1186/s12886-017-0485-4 RESEARCH ARTICLE Open Access Correlation between short- and long-term effects of intravitreal ranibizumab therapy on macular edema
More informationResearch Article Efficacy and Safety in Retinal Vein Occlusion Treated with at Least Three Consecutive Intravitreal Dexamethasone Implants
Ophthalmology Volume 2016, Article ID 6016491, 6 pages http://dx.doi.org/10.1155/2016/6016491 Research Article Efficacy and Safety in Retinal Vein Occlusion Treated with at Least Three Consecutive Intravitreal
More informationFA Conference. Lara Rosenwasser Newman, M.D. 10/2/14 University of Louisville Department of Ophthalmology and Visual Sciences
FA Conference Lara Rosenwasser Newman, M.D. 10/2/14 University of Louisville Department of Ophthalmology and Visual Sciences Patient Presentation CC: (sent by optometrist) Blurry/foggy vision HPI: 62 yo
More informationCDEC FINAL RECOMMENDATION
CDEC FINAL RECOMMENDATION RANIBIZUMAB (Lucentis Novartis Pharmaceuticals Canada Inc.) New Indication: Macular Edema Secondary to Retinal Vein Occlusion Recommendation: The Canadian Drug Expert Committee
More informationBMJ Open. For peer review only -
Comparative efficacy and safety of treatments for macular oedema secondary to branch retinal vein occlusion: a network meta-analysis Journal: Manuscript ID: bmjopen-0-00 Article Type: Research Date Submitted
More informationTREATMENT STRATEGIES FOR CHORIORETINAL VASCULAR DISEASES: ADVANTAGES AND DISADVANTAGES OF INDIVIDUALISED THERAPY
TREATMENT STRATEGIES FOR CHORIORETINAL VASCULAR DISEASES: ADVANTAGES AND DISADVANTAGES OF INDIVIDUALISED THERAPY *Michael W. Stewart Professor and Chairman, Mayo School of Medicine, Department of Ophthalmology,
More informationStephen M. Holland 1,2,3, David G. Dodwell 1,2ˆ, Darrel A. Krimmel 1,4 and Christopher M. de Fiebre 5*
Holland et al. BMC Ophthalmology (2015) 15:117 DOI 10.1186/s12886-015-0107-y RESEARCH ARTICLE Open Access Retrospective analyses of optical coherence tomography in recurrent macular edema following intravitreal
More informationThe Era of anti- - - VEGF Kirk L. Halvorson, OD
The Era of anti- - - VEGF Kirk L. Halvorson, OD Introduction: Anti- - - Vascular Endothelial Growth Factor (Anti- - - VEGF) medication is a relatively a new line of medications used in treating a variety
More informationPharmaceutical quality of reformulated bevacizumab as used in eye conditions in general.
The Royal College of Ophthalmologists 17 Cornwall Terrace, London. NW1 4QW. Telephone: 020-7935 0702 Facsimile: 020-7935 9838 Website: WWW.RCOPHTH.AC.UK PATRON HRH THE DUKE OF YORK, KG, KCVO, ADC The Royal
More informationApplying New Data to Improve the Standard of Care in Retinal Disease. With articles by Gaurav K. Shah, MD Carl D. Regillo, MD.
Supplement to July/August 2012 CME Activity Applying New Data to Improve the Standard of Care in Retinal Disease With articles by Gaurav K. Shah, MD Carl D. Regillo, MD Release date: August 2012. Expiration
More informationEfficacy and safety of Pro Re Nata regimen without loading dose ranibizumab injections in retinal vein occlusion
Open Access Original Article Efficacy and safety of Pro Re Nata regimen without loading dose ranibizumab injections in retinal vein occlusion Erkan Unsal 1, Kadir Eltutar 2, Pınar Sultan 3, Hulya Gungel
More informationThe Common Clinical Competency Framework for Non-medical Ophthalmic Healthcare Professionals in Secondary Care
The Common Clinical Competency Framework for Non-medical Ophthalmic Healthcare Professionals in Secondary Care Cataract November 2016 Association of Health Professions in Ophthalmology General basic competences
More informationCombination Treatment of Diabetic Macular Edema with Anti-Vascular Endothelial Growth Factor and Steroids: Analysis of DRCR.
REVIEW ARTICLE Combination Treatment of Diabetic Macular Edema with Anti-Vascular Endothelial Growth Factor and Steroids: Analysis of DRCR.net Protocol U Cindy Ung 1, Kareem Moussa 1, Yoshihiro Yonekawa
More informationIntravitreal Injection
for patients Eye Clinic Ipswich Hospital Tel: 01473 703230 Intravitreal Injection What is an intravitreal injection? An intravitreal injection is the injection of a drug into the vitreous body (the jelly
More informationDexamethasone Intravitreal Implant Rescue Treatment for Bevacizumab Refractory Macular Edema Secondary to Branch Retinal Vein Occlusion
pissn: 1011-8942 eissn: 2092-9382 Korean J Ophthalmol 2017;31(2):108-114 https://doi.org/10.3341/kjo.2017.31.2.108 Original Article Dexamethasone Intravitreal Implant Rescue Treatment for Bevacizumab Refractory
More informationApplications of Sustained Release Delivery Systems in Ocular Disease
Applications of Sustained Release Delivery Systems in Ocular Disease Formulation and Delivery Systems For Peptide and Protein 2012 December 5, 2012 Christopher A. Rhodes, Ph.D. Principal, Christopher A
More informationPosterior Segment Macular Edema
Posterior Segment Macular Edema Treatment of Macular Edema following Branch Retinal Vein Occlusion Raafay Sophie, MD 1 and Peter A Campochiaro, MD 2 1. Post-doctoral Fellow; 2. Eccles Professor of Ophthalmology
More informationInternational Journal of Health Sciences and Research ISSN:
International Journal of Health Sciences and Research www.ijhsr.org ISSN: 2249-9571 Original Research Article A Multivariate Analysis of Intravitreal Injection of Anti-VEGF Bevacizumab in the Treatment
More informationCase Report Inherent Challenges in Managing Long Standing Refractory Diabetic Macular Edema
Cronicon OPEN ACCESS EC OPHTHALMOLOGY Case Report Inherent Challenges in Managing Long Standing Refractory Diabetic Macular Edema V Swetha E Jeganathan 1,2 * and Karen Madill 3 1 Department of Ophthalmology,
More information황반부부종을동반한분지망막정맥폐쇄의치료에있어서유리체강내베바시주맙의반응을예측하는인자
Journal of Retina 2018;3(1):20-25 ORIGINAL ARTICLE pissn 2508-1926 eissn 2508-3589 황반부부종을동반한분지망막정맥폐쇄의치료에있어서유리체강내베바시주맙의반응을예측하는인자 Predictive Factors for a Favorable Response to Intravitreal Bevacizumab for
More informationFacts About Diabetic Eye Disease
Facts About Diabetic Eye Disease Points to Remember 1. Diabetic eye disease comprises a group of eye conditions that affect people with diabetes. These conditions include diabetic retinopathy, diabetic
More informationUpdates and Controversies
Updates and Controversies Philippine Journal of OPHTHALMOLOGY Vascular endothelial growth factor (VEGF) and inflammation. VEGF-A circulates normally in the body and is essential in endothelial cell growth.
More informationVenous Occlusive Diseases
Venous Occlusive Diseases Bruce R. Saran, MD Adjunct Assistant Clinical Professor of Medicine Scheie Eye Institute University of Pennsylvania School of Medicine Philadelphia, PA -a division of: RVO Demographics
More informationThe Trust does not record electronically the number of patients who are treated by laser for a condition.
Ref: FOI/CAD/ID 3224 06 April 20 Please reply to: FOI Administrator Trust Management Maidstone Hospital Hermitage Lane Maidstone Kent ME 9QQ Email: mtw-tr.foiadmin@nhs.net Freedom of Information Act 2000
More informationEfficacy and timing of adjunctive therapy in the anti-vegf treatment regimen for macular oedema in retinal vein occlusion: 12-month real-world result
OPEN (2018) 32, 537 545 Official journal of The Royal College of Ophthalmologists www.nature.com/eye Efficacy and timing of adjunctive therapy in the anti-vegf treatment regimen for macular oedema in retinal
More informationThe Common Clinical Competency Framework for Non-medical Ophthalmic Healthcare Professionals in Secondary Care
The Common Clinical Competency Framework for Non-medical Ophthalmic Healthcare Professionals in Secondary Care Acute & Emergency Care November 2016 Association of Health Professions in Ophthalmology General
More informationDiabetic Macular Oedema To treat or not to treat?
Diabetic Macular Oedema To treat or not to treat? Ms Ranjit Sandhu MBBS MRCOphth MD FRCOphth Consultant Ophthalmic Surgeon Cataract Surgery, Medical Retina & Uveitis The Luton and Dunstable University
More informationEfficacy of combined intravitreal bevacizumab and triamcinolone for branch retinal vein occlusion
AOP*** 1 Original Article Efficacy of combined intravitreal bevacizumab and triamcinolone for branch retinal vein occlusion Rasha I Ali1, Kapil G Kapoor 1,2, Adeel N Khan 1, Syed K Gibran 1 Purpose: To
More informationOpthea Initiates OPT-302 Diabetic Macular Edema Clinical Trial
ASX and Media Release 3 January 2018 Opthea Initiates OPT-302 Diabetic Macular Edema Clinical Trial Melbourne, Australia; January 3 2018 Opthea Limited (ASX:OPT), a late stage biopharmaceutical company
More informationSustained-Release Corticosteroid Options
Sustained-Release Corticosteroid Options Mariana Cabrera, University of Miami Miller School of Medicine Steven Yeh, Emory University Thomas A Albini, University of Miami Miller School of Medicine Journal
More informationOphthalmologic Policy. Vascular Endothelial Growth Factor (VEGF) Inhibitors
Ophthalmologic Policy UnitedHealthcare Commercial Drug Policy Vascular Endothelial Growth Factor (VEGF) Inhibitors Policy Number: 2016D0042H Effective Date: October 1, 2016 Table of Contents Page INSTRUCTIONS
More informationMedical Coverage Policy Intravitreal Corticosteroid Implants)
Medical Coverage Policy Intravitreal Corticosteroid Implants) EFFECTIVE DATE:10 01 2015 POLICY LAST UPDATED: 02 07 2017 OVERVIEW An intravitreal implant is a drug delivery system, injected or surgically
More informationSMC briefing note. The following medicines were accepted for use: The following medicine has not been recommended for use: About SMC.
Monthly briefings are produced in order to help members of the media and other interested people understand the work and advice of the Scottish Medicines Consortium. The detailed advice for each medicine
More informationDarren J. Bell, M.D. Texas A&M University College of Medicine College Station, Texas Doctor of Medicine
Darren J. Bell, M.D. Education Texas A&M University College of Medicine College Station, Texas Doctor of Medicine 1997-2001 Texas A&M University College Station, Texas Bachelor of Science, Biomedical Engineering
More informationManagement of Neovascular AMD
Kapusta AMD Part 1 Management of Neovascular AMD Dr. Michael A. Kapusta, MD, FRCSC Ophthalmologist in Chief Jewish General Hospital Vitreoretinal Surgeon 1 FINANCIAL DISCLOSURES Consulting honoraria Bayer,
More informationTHE ROLE OF anti-vegf IN DIABETIC RETINOPATHY AND AGE RELATED MACULAR DEGENERATION
THE ROLE OF anti-vegf IN DIABETIC RETINOPATHY AND AGE RELATED MACULAR DEGENERATION MOESTIDJAB DEPARTMENT OF OPHTHALMOLOGY SCHOOL OF MEDICINE AIRLANGGA UNIVERSITY DR SOETOMO HOSPITAL SURABAYA INTRODUCTION
More informationFDA approves Roche s Lucentis (ranibizumab injection) for treatment of diabetic retinopathy in people with diabetic macular edema
Media Release Basel, 9 February 2015 FDA approves Roche s Lucentis (ranibizumab injection) for treatment of diabetic retinopathy in people with diabetic macular edema First eye medicine approved for treatment
More informationThe Common Clinical Competency Framework for Non-medical Ophthalmic Healthcare Professionals in Secondary Care
The Common Clinical Competency Framework for Non-medical Ophthalmic Healthcare Professionals in Secondary Care Glaucoma November 2016 Association of Health Professions in Ophthalmology General basic competences
More informationPatient information Eylea treatment for diabetic macular oedema (DMO)
Patient information Eylea treatment for diabetic macular oedema (DMO) Introduction The doctor has found that you have swelling affecting the centre of the retina at the back of your eye. This is known
More informationmeasure of your overall performance. An isolated glucose test is helpful to let you know what your sugar level is at one moment, but it doesn t tell you whether or not your diabetes is under adequate control
More informationCorporate Medical Policy
Corporate Medical Policy Intravitreal Implant File Name: Origination: Last CAP Review: Next CAP Review: Last Review: intravitreal_implant 11/2010 6/2017 6/2018 6/2017 Description of Procedure or Service
More informationSECTION A Clarifications of the clinical data:
SECTION A Clarifications of the clinical data: A1. The submission lists two exploratory outcomes that are not listed in the Clinical Study Reports for BRAVO and CRUISE: (i) the proportion of patients who
More informationRetinal vein occlusion (RVO) is a vascular disease
INTRAVITREAL RANIBIZUMAB FOR RETINAL VEIN OCCLUSION THROUGH 1 YEAR IN CLINICAL PRACTICE TROELS BRYNSKOV, MD,* HENRIK KEMP, MD,* TORBEN L. SØRENSEN, MD, DMSC* Purpose: To evaluate the efficacy and safety
More informationIntroduction How the eye works
1 Introduction Diabetic retinopathy is a condition that can cause permanent loss of eyesight and even blindness. It is a major cause of loss of vision. But if a person with diabetes receives proper eye
More informationResearch Article http://www.alliedacademies.org/clinical-ophthalmology-and-vision-science/ The trial: A pilot study to assess the efficacy, durability, and safety of combination ranibizumab + peripheral
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Lucentis) Reference Number: CP.PHAR.186 Effective Date: 03.16 Last Review Date: 02.18 Line of Business: Commercial, Medicaid Coding Implications Revision Log See Important Reminder at
More informationRegulation of products for Macular Oedema EYE 2011, EMA
Safeguarding public health Regulation of products for, EMA David Silverman, Clinical Assessor, MHRA 27 October 2011 Points to be covered Length & number of studies Trial population Endpoints Comparators
More informationUniversity of Bristol - Explore Bristol Research. Peer reviewed version. Link to published version (if available): /s
Theodoropoulou, S., Ellabban, A. A., Johnston, R. L., Cilliers, H., Mohamed, Q., & Sallam, A. B. (2017). Short-term safety of dexamethasone implant for treatment of macular edema due to retinal vein occlusion,
More informationAbicipar pegol for wet age related macular degeneration
EVIDENCE BRIEFING AUGUST 2018 Abicipar pegol for wet age related macular degeneration NIHRIO ID 7084 NICE ID 9724 Developer/Company Allergan Ltd and Molecular Partners UKPS ID 646978 Licensing and market
More informationCataract and Diabetic macular edema: What should I do?
Cataract and Diabetic macular edema: What should I do? Irini Chatziralli Ophthalmic Surgeon, University Scholar 2 nd Department of Ophthalmology, University of Athens (Director: Prof P. Theodossiadis)
More informationCentral retinal vein occlusion: modifying current treatment protocols
(2016) 30, 505 514 2016 Macmillan Publishers Limited All rights reserved 0950-222X/16 www.nature.com/eye Central retinal vein occlusion: modifying current treatment protocols M Ashraf 1, AAR Souka 1 and
More informationBevacizumab versus Dexamethasone Implant Followed by Bevacizumab for the Treatment of Macula Edema Associated with Branch Retinal Vein Occlusion
pissn: 1011-8942 eissn: 2092-9382 Korean J Ophthalmol 2018;32(1):29-37 https://doi.org/10.3341/kjo.2016.0134 Original Article Bevacizumab versus Dexamethasone Implant Followed by Bevacizumab for the Treatment
More informationThe effect of a single intravitreal implantation of dexamethasone on the fellow eye in bilateral non-infectious uveitis case report
European Review for Medical and Pharmacological Sciences The effect of a single intravitreal implantation of dexamethasone on the fellow eye in bilateral non-infectious uveitis case report J. CISZEWSKA,
More informationSerious Eye diseases, New treatments. Mr. M. Usman Saeed MBBS, FRCS, FRCOphth Consultant Ophthalmologist
Serious Eye diseases, New treatments Mr. M. Usman Saeed MBBS, FRCS, FRCOphth Consultant Ophthalmologist 5 major causes of loss of vision Cataracts Glaucoma Macular degeneration Retinal Vein occlusions
More informationThere are no published randomized, double-blind trials comparing aflibercept to other therapies in neovascular AMD.
Subject: Eylea (aflibercept) Original Effective Date: 7/11/2014 Policy Number: MCP-191 Revision Date(s): 10/11/2016 Review Date(s): 12/16/2015; 10/11/2016, 6/22/2017, 7/10/2018 DISCLAIMER This Medical
More informationDiabetic Retinopatathy
Diabetic Retinopatathy Jay M. Haynie, OD, FAAO Financial Disclosure I have received honoraria or am on the advisory board for the following companies: Carl Zeiss Meditec Arctic DX Macula Risk Advanced
More informationOPHTHALMOLOGIC POLICY: VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) INHIBITORS
UnitedHealthcare Commercial Medical Benefit Drug Policy OPHTHALMOLOGIC POLICY: VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) INHIBITORS Policy Number: PHA020 Effective Date: September 1, 2018 Table of Contents
More informationDiabetic Retinopathy: Recent Advances in Treatment and Treatment Approaches
Diabetic Retinopathy: Recent Advances in Treatment and Treatment Approaches Dr. David Wong Associate Professor Retina Specialist, Department of Ophthalmology & Vision Sciences, University of Toronto, Canada
More informationA ROUNDTABLE DISCUSSION FEATURING:
Jointly sponsored by the Dulaney Foundation and Retina Today. Supplement to October 2009 New and Emerging Treatment Paradigms for Macular Edema in Retinal Vein Occlusion and Diabetic Retinopathy A ROUNDTABLE
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE Dexamethasone intravitreal implant (Ozurdex ) for the treatment of macular oedema caused by retinal vein occlusion Single technology appraisal (STA)
More informationBevacizumab for Macular Edema in Central Retinal Vein Occlusion: A Prospective, Randomized, Double-Masked Clinical Study
Bevacizumab for Macular Edema in Central Retinal Vein Occlusion: A Prospective, Randomized, Double-Masked Clinical Study David L.J. Epstein, MD, Peep V. Algvere, MD, PhD, Gunvor von Wendt, MD, PhD, Stefan
More informationCommon Drug Review Patient Group Input Submissions
Common Drug Review Patient Group Input Submissions Aflibercept (Eylea) for Age-related Macular Degeneration Patient group input submissions were received from the following patient groups. Those with permission
More informationSuprachoroidal Triamcinolone Acetonide for Retinal Vein Occlusion: Results of the Tanzanite Study
Suprachoroidal Triamcinolone Acetonide for Retinal Vein Occlusion: Results of the Tanzanite Study Peter A. Campochiaro, MD, 1 Charles C. Wykoff, MD, 2 David M. Brown, MD, 2 David S. Boyer, MD, 3 Mark Barakat,
More information